医疗机构中成药遴选专家共识(第一版)

程杰, 关胜江, 曹俊岭, 陈树和, 高山, 高雪亮, 郭晓秋, 韩晟, 何婷, 孔祥文, 李国辉, 李学林, 李亚秋, 林华, 刘力, 马致洁, 欧阳荣, 沈夕坤, 孙洪胜, 唐洪梅, 唐进法, 王乐, 王世伟, 吴剑坤, 辛义周, 薛春苗, 闫国强, 晏军, 杨毅恒, 姚毅, 伊博文, 赵奎军, 赵旭, 张颖, 郑倩, 赵生俊

中国药学杂志 ›› 2022, Vol. 57 ›› Issue (18) : 1580-1586.

PDF(1004 KB)
PDF(1004 KB)
中国药学杂志 ›› 2022, Vol. 57 ›› Issue (18) : 1580-1586. DOI: 10.11669/cpj.2022.18.013
论著

医疗机构中成药遴选专家共识(第一版)

  • 程杰1, 关胜江1, 曹俊岭2*, 陈树和3, 高山4, 高雪亮1, 郭晓秋5, 韩晟6, 何婷2, 孔祥文7, 李国辉8, 李学林9, 李亚秋10, 林华11, 刘力12, 马致洁13, 欧阳荣14, 沈夕坤15, 孙洪胜16, 唐洪梅17, 唐进法18, 王乐2, 王世伟19, 吴剑坤20, 辛义周16, 薛春苗2, 闫国强2, 晏军2, 杨毅恒22, 姚毅23, 伊博文24, 赵奎军25, 赵旭26, 张颖27, 郑倩28, 赵生俊29
作者信息 +
文章历史 +

引用本文

导出引用
程杰, 关胜江, 曹俊岭, 陈树和, 高山, 高雪亮, 郭晓秋, 韩晟, 何婷, 孔祥文, 李国辉, 李学林, 李亚秋, 林华, 刘力, 马致洁, 欧阳荣, 沈夕坤, 孙洪胜, 唐洪梅, 唐进法, 王乐, 王世伟, 吴剑坤, 辛义周, 薛春苗, 闫国强, 晏军, 杨毅恒, 姚毅, 伊博文, 赵奎军, 赵旭, 张颖, 郑倩, 赵生俊. 医疗机构中成药遴选专家共识(第一版)[J]. 中国药学杂志, 2022, 57(18): 1580-1586 https://doi.org/10.11669/cpj.2022.18.013
中图分类号: R287   

参考文献

[1] DIAO H X, GUO Z L, ZHAN R T,et al. Investigation and Analysis on the current situation of the use of Chinese patent medicine in China[J].China Pract Med(中国实用医药),2010,5(36):14-16.
[2] LI Z X, DUAN R. Research status and reflection of methods and tools for drug selection and evaluation in medical institutions from China[J]. Eval Anal Drug Use Hosp China(中国医院用药评价与分析),2022,22(3):257-260,264.
[3] ZHANG Q, WANG Z F, XIE Y M,et al. Technical specification for clincal comprehensive evaluation of Chinese patent medicine[J].World Chin Med(世界中医药),2021,16(22):3394-3397,3403.
[4] ZHAO Z G, DONG Z J, LIU J P.A Quick guideline for drug evaluation and selection in Chinese medical institutions[J].Her Med(医药导报),2020,39(11):1457-1465.
[5] Guangdong Pharmaceutical Association. Expert consensus on statin evaluation and selection in Guangdong Province[J/OL]. Pharm Today(今日药学):1-17[2022-04-09].http://kns.cnki.net/kcms/detail/44.1650.R.20220106.1422.002.html.
[6] SHU Y C, TIAN L, TAN X Y.Jiangsu expert consensus on the formation of evaluation index system for variety selection and clinical application of Chinese patent medicine in medical institutions[J]. J China Pharm(中国药房), 2022,33(2):129-135.
[7] National Health Commission. Notice on carrying out drug use monitoring and clinical comprehensive evaluation[EB/OL]. [2019-04-09]. http://www.nhc.gov.cn/yaozs/pqt/201904/31149bb1845e4c019a04f30c0d69c2c9.shtml.
[8] National Health Commission. Notice on printing and distributing the opinions on Strengthening Drug Administration in medical institutions and promoting rational drug use[EB/OL]. [2020-02-26].http://www.satcm.gov.cn/xinxifabu/shizhengyaowen/2020-02-26/13420.html.
[9] National Medical Products Administration. Implementation Opinions on promoting the inheritance, innovation and development of traditional Chinese Medicine[EB/OL]. [2020-12-25]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/202012251 6390 6151.html.
[10] National Health Commission. Notice on standardizing the comprehensive clinical evaluation of drugs[EB/OL]. [2021-07-28].http://wsjkw.hebei.gov.cn/zcfg2/380991.jhtml.
[11] ZHANG H L, JIAO L W, LIANG N,et al. Construction of multi dimension and multi criteria evaluation index system for superior Chinese patent medicines based on comprehensive evaluation method[J]. J Basic Chin Med(中国中医基础医学杂志),2021,27(3):403-406.
[12] Annual report of national adverse drug reaction monitoring(2021)[EB/OL]. [2022-03-30].https://www.cdr-adr.org.cn/tzgg_home/202203/t20220330_49585.html.
[13] ZHAO W M, YANG Y, TIAN K. Analysis on the health technology assessment of traditional Chinese medicine[J]. Guid J Tradit Chin Med Pharm(中医药导报),2019,25(21):131-134.
[14] QIAO J H, YANG P, DONG L,et al. The application of real world study in the safety evaluation of Chinese patent medicine after marketing[J].Chin New Drugs J(中国新药杂志),2021, 30(9):769-772.
[15] DANG H X, LIU J, LI B,et al. The research on the value framework of Chinese patent medicine[J]. Chin New Drugs J(中国新药杂志),2021,30(11):961-970.
[16] LI G, GUO Y B, LI W S, et al. Summary of competitiveness report on science and technology of big brand traditional Chinese medicine (2019 Edition)[J]. Mod Chin Med(中国现代中药), 2020,22(1):1-20.
[17] DRUMMOND M F, SCULPHER M J, CLAXTON K, et al. Methods for the Economic Evaluation of Care Programms[M].4th ed.Oxford: Oxford University Press,2015:16-19.
[18] TANG J Y. Thoughts and suggestions on registration and classification of traditional Chinese medicines[J]. China J Chin Mater Med(中国中药杂志),2020,45(16):4004-4008.
[19] CHEN Y H, LING X, LI C X,et al. Discussion on research ideas of post-marketing clinical re-evaluation of traditional Chinese medicine[J].Chin New Drugs J(中国新药杂志),2021,30(24):2262-2267.
[20] ZHOU Y H, SONG M X, SHEN X R,et al. The current situation of instructions regarding storage conditions of marketed Chinese patent medicines and the discussions on related problems[J].Chin New Drugs J(中国新药杂志), 2022,31(1):18-26.
[21] QIAN P P, CAO K, ZHAO L,et al. Discussion on shelf life and in-use period of medicinal products[J].Chin J Pharmacovigil(中国药物警戒),2018,15(07):414-418.
[22] ZENG J, YANG A D, ZHANG A J,et al. Registration management and analysis of high-quality transformation factors of traditional Chinese medicine compound preparations of ancient classic prescriptions[J].Pharmacol Clin Chin Mater Med(中药药理与临床),2020,36(3):242-254.
[23] SONG Z, WANG Z F, WU Y,et al. Thoughts on post marketing evaluation of classic famous Chinese patent medicines based on clinical value[J]. China J Chin Mater Med(中国中药杂志),2021,46(8):1988-1993.
[24] WANG L L, HU L F, ZHANG X D,et al.Analysis on approval of new Chinese medicine applied for investigational new drug from 2005 to 2020[J].Chin Tradit Herb Drugs(中草药),2021,52(12):3765-3774.
[25] BAI X, ZHANG Q, WANG F,et al. On the way of writing the names of raw and processed products in traditional Chinese medicine patent applications[J]. Chin J Inf Tradit Chin Med(中国中医药信息杂志),2013,20(1):4-5.
[26] CAO J L, LI X L, MENG F,et al.Expert consensus on clinical application of Chinese herbal medicine decoction pieces(First Edition)[J]. China J Chin Mater Med(中国中药杂志), 2020,45(13):3238-3244.
[27] YAN J. Investigation and analysis of function and indication in 242 package inserts of Chinese patent medicine[J]. J China Pharm(中国药房),2012,23(44):4151-4153.
[28] Ch.P VolⅠ(2020)(中国药典2020年版.一部)[S].2020.
[29] ZHUANG J, ZHANG L P. Thoughts on the expression of the main functional items in the manual of Chinese patent medicine[J].China J Chin Mater Med(中国中药杂志),2001(7):68-71.
[30] MENG F, LI X L.Discussion on Chinese medicine proprietary specifi cation term representation method[J].Clin J Tradit Chin Med(中医药临床杂志),2015,27(1):111-112.
[31] CPC Central Committee and State Council. Opinions on promoting the inheritance, innovation and development of traditional Chinese Medicine[EB/OL]. [2019-10-26].http://www.gov.cn/zhengce/2019-10/26/content_5445336.htm.

基金

北京市中医药改革专项资助(201806);河北省中医药管理局指令性科研计划项目资助(2022027)
PDF(1004 KB)

Accesses

Citation

Detail

段落导航
相关文章

/